BOLT (Bolt Biotherapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by BOLT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-11 | NICOLE ONETTO | Director | A | — | — |
| 2026-06-11 | BRIAN O'CALLAGHAN | Director | A | — | — |
| 2026-06-11 | Laura Berner | Director | A | — | — |
| 2026-06-11 | KATHLEEN LAPORTE | Director | A | — | — |
| 2026-06-11 | Jakob Dupont | Director | A | — | — |
| 2026-02-04 | Grant Yonehiro | Chief Operating Officer | A | — | — |
| 2026-02-04 | Sarah Nemec | Senior VP, Finance and PAO | Buy | — | — |
| 2026-02-04 | William P. Quinn | President, CEO and CFO | Buy | — | — |
| 2025-12-16 | Laura Berner | Director | MIXED | — | — |
| 2025-12-16 | NICOLE ONETTO | Director | MIXED | — | — |
| 2025-12-16 | KATHLEEN LAPORTE | Director | MIXED | — | — |
| 2025-12-16 | Jakob Dupont | Director | MIXED | — | — |
| 2025-12-16 | Grant Yonehiro | Chief Operating Officer | MIXED | — | — |
| 2025-12-16 | William P. Quinn | President, CEO and CFO | MIXED | — | — |
| 2025-12-16 | Sarah Nemec | Senior VP, Finance and PAO | MIXED | — | — |
| 2025-12-16 | BRIAN O'CALLAGHAN | Director | MIXED | — | — |
| 2025-10-24 | Sarah Nemec | Senior VP, Finance and PAO | MIXED | — | — |
| 2025-10-24 | Grant Yonehiro | Chief Operating Officer | A | — | — |
| 2025-10-24 | William P. Quinn | President, CEO and CFO | MIXED | — | — |
| 2025-07-02 | Laura Berner | Director | A | — | — |
| 2025-07-02 | Jakob Dupont | Director | A | — | — |
| 2025-07-02 | KATHLEEN LAPORTE | Director | A | — | — |
| 2025-07-02 | BRIAN O'CALLAGHAN | Director | A | — | — |
| 2025-07-02 | NICOLE ONETTO | Director | A | — | — |
| 2025-05-05 | Jakob Dupont | Director | A | — | — |
| 2025-05-05 | Grant Yonehiro | Chief Operating Officer | A | — | — |
| 2025-05-05 | Sarah Nemec | Senior VP, Finance and PAO | Buy | — | — |
| 2025-05-05 | William P. Quinn | President, CEO and CFO | Buy | — | — |
| 2024-09-06 | Jakob Dupont | Director | A | — | — |
| 2024-07-24 | Grant Yonehiro | Chief Operating Officer | A | — | — |
| 2024-07-24 | William P. Quinn | President, CEO and CFO | A | — | — |
| 2024-07-24 | Sarah Nemec | VP, Finance and PAO | A | — | — |
| 2024-06-14 | Laura Berner | Director | A | — | — |
| 2024-06-14 | JAMES HEALY | Director | A | — | — |
| 2024-06-14 | BRIAN O'CALLAGHAN | Director | A | — | — |
| 2024-06-14 | KATHLEEN LAPORTE | Director | A | — | — |
| 2024-06-14 | NICOLE ONETTO | Director | A | — | — |
| 2024-06-14 | MAHENDRA SHAH | Director | A | — | — |
| 2024-06-14 | Frank D. Lee | Director | A | — | — |
| 2024-03-06 | Edith A. Perez | Chief Medical Officer | A | — | — |
| 2024-03-06 | Grant Yonehiro | Chief Business Officer | A | — | — |
| 2024-03-06 | William P. Quinn | Chief Financial Officer | A | — | — |
| 2024-03-06 | Randall C Schatzman | Chief Executive Officer | A | — | — |
| 2023-12-13 | William P. Quinn | Chief Financial Officer | Buy | — | — |
| 2023-12-01 | EDGAR ENGLEMAN | Director | Sell | — | — |
| 2023-11-22 | EDGAR ENGLEMAN | Director | Sell | — | — |
| 2023-11-22 | Vivo Opportunity, LLC | 10%+ Owner | Sell | — | — |
| 2023-11-20 | EDGAR ENGLEMAN | Director | Sell | — | — |
| 2023-11-20 | Vivo Capital VIII, LLC | 10%+ Owner | Sell | — | — |
| 2023-06-14 | Laura Berner | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 185,200 | — |
| — | 10%+ Owner | 137,722 | — |
| — | Director | 115,222 | — |
| — | Director | 71,532 | — |
| — | Chief Operating Officer | 38,918 | — |
| — | Director | 13,323 | — |
| — | 10%+ Owner | 9,908 | — |
| — | 10%+ Owner | 7,179 | — |
| — | 10%+ Owner | 5,583 | — |
| — | President, CEO and CFO | 2,313 | — |
| — | Senior VP, Finance and PAO | 1,415 | — |
| — | Director | 110 | — |
| — | Chief Executive Officer | 75 | — |
| — | Director | 60 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BOLT quote page; the site-wide leaderboard is on the insider transactions hub.